公开(公告)号：US10744116B2

公开(公告)日：2020-08-18

申请号：US16084911

申请日：2017-03-16

Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Inventor： Roger S. Lo ,  Willy Hugo ,  Antoni Ribas ,  Jesse Zaretsky

IPC: G01N31/00 ,  A61K31/385 ,  C12Q1/6886 ,  C07K16/28 ,  G16B20/00 ,  A61P35/00 ,  G16B5/00 ,  G16B25/00 ,  A61K31/337 ,  A61K31/427 ,  A61K39/395 ,  A61K45/06 ,  C12Q1/686 ,  G16B25/10

Abstract: Methods of predicting or detecting sensitivity to therapeutic effects of anti-PD-1 therapy in a patient suffering from melanoma, as well as for selecting somatic mutanomes and transcriptomes of melanoma biopsies. A tumor sample obtained from the patient is assayed for a measure of anti-PD-1 therapy sensitivity via, for example, whole transcriptome sequencing, antibody based protein quantifications, mass spectrometry based protein quantification, targeted mRNA sequencing, real-time RT-PCR, Sanger sequencing, targeted sequencing and/or whole exome/genome sequencing. Samples are selected that exhibit a higher first enrichment similarity score and/or a lower second enrichment similarity score, and/or at least one measure of sensitivity. A patient whose sample was selected herein as a candidate for anti-PD-1 therapy is thereby identified. The method of the invention can further comprise treating the patient with anti-PD-1 therapy, optionally in conjunction with combinatorial therapy.